First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial 4ST. GALLEN, Switzerland, May 23, 2025 /PRNewswire/ -- CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as an option t ...

Travere Therapeutics (TVTX) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Victoria Prescott - Investor RelationsEric Dube - President and Chief Executive OfficerJula Inrig - Chief Medical OfficerPeter Heerma - Chief Commercial OfficerChris Cline - Chief Financial OfficerWilliam Rote - Chief Research OfficerWill Soghikian - Vice President - Equity ResearchLaura Chico - Managing Director, Equity ResearchLiisa Bayko - Managing DirectorGreg Harrison - Director - BiotechnologySadia Rahman - ...